Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: AI
The Democratic Republic of the Congo (DRC) is battling one of its deadliest Ebola outbreaks in recent years. While it is driving innovation in medical science with new clinical trials and diagnostic tests, it is also a stark reminder of the urgency to contain the outbreak as soon as possible.
According to the latest data, the death toll in DRC has now crossed 500 with at least 1,528 cases that are reported and confirmed.
While Ebola is not a new disease, the current outbreak stands apart because it is being caused by a rare strain of the virus, Bundibugyo.
Unlike previous outbreaks dominated by the Zaire strain of Ebola, the current epidemic, caused by the Bundibugyo virus, is a much less common species of the Ebola virus family.
The rarity of the strain has created unique scientific and emergency public health challenges, as there is currently no licensed vaccine designed to protect against Bundibugyo Ebola virus.
During outbreaks caused by the Zaire strain, vaccination became an important part of outbreak control. In the current epidemic, however, public health officials are being forced to rely heavily on rapid diagnosis, infection prevention, surveillance, and existing medical care.
Read more: Legionnaires' Disease Outbreak Grips NYC After At Least 14 Cases Reported Across 2 Neighborhoods
In a major scientific breakthrough, the World Health Organization (WHO) recently added the first molecular diagnostic test for the Bundibugyo Ebola virus to its Emergency Use Listing (EUL).
The test detects the virus's genetic material in blood samples, enabling laboratories to confirm infections more quickly and accurately.
WHO and its partners have launched the first clinical trial specifically evaluating treatments for Bundibugyo Ebola virus disease.
Researchers are testing the experimental monoclonal antibody MBP134, the antiviral drug remdesivir, and a combination of both to determine whether they can improve survival.
The Bundibugyo virus was first identified in Uganda in 2007 and has caused only a few outbreaks since then. As infections have been relatively uncommon compared to the Zaire strain, researchers have had limited opportunities to develop vaccines, treatments and diagnostic tests.
Due to this, healthcare workers have been compelled to rely primarily on rapid isolation of patients, intensive supportive care, contact tracing, and strict infection prevention measures to slow transmission.
Currently, Eastern DRC is the hotspot for the Bundibugyo Ebola outbreak, where conflict, population displacement, skepticism, and insecurity have made it difficult for health workers to reach affected locations.
Here, access to healthcare still remains uneven in many areas. Additionally, movement of people across districts and states in the country can accelerate the spread of infection significantly.
As scientists race to validate new diagnostics and evaluate experimental treatments, the Bundibugyo outbreak is becoming more than a public health emergency. It is also serving as a critical test of how quickly the global health community can develop and deploy new tools against an emerging infectious disease.
Credit: AI
The health authorities in New York City are currently investigating an outbreak of Legionnaires' disease after at least 14 people were diagnosed with the potentially life-threatening respiratory illness across two neighborhoods in Manhattan. The recent outbreak prompted an urgent public health response.
The outbreak, initially marked with just two cases earlier this week, has grown rapidly. Cases of infections were reported in Carnegie Hill and Yorkville on the Upper East Side.
The New York City Department of Health has immediately launched an investigation to identify the source of the outbreak and is inspecting cooling towers and other water systems in the affected areas, where the Legionella bacteria commonly thrive.
Authorities have urged residents and visitors who were in the neighborhoods in recent days to seek medical attention if they face symptoms like fever, cough or difficulty breathing.
The bacteria naturally occur in freshwater environments but can multiply in man-made water systems that are poorly maintained, including:
Read more: New Blood Test May Predict Alzheimer's Symptoms At Least 4 Years In Advance: Study
Symptoms of Legionnaire's disease appear 2 to 14 days after exposure, although they can sometimes take longer. The common symptoms of Legionnaires' disease include:
Some patients, particularly older adults, may also develop nausea, vomiting, diarrhea or confusion. As the illness closely resembles other forms of pneumonia, laboratory testing is usually required to confirm the diagnosis.
Read more: Donald Trump Posts AI Video of Himself Treating Critics for 'Derangement Syndrome'
Legionnaires' disease is treatable with antibiotics, and early diagnosis greatly improves recovery. However, delayed treatment can lead to severe complications such as respiratory failure, septic shock, or multi-organ failure.
The disease can be fatal, especially among older adults and people with underlying health conditions.
While the overall fatality rate is around 10% in otherwise healthy individuals, it can be considerably higher in vulnerable patients if treatment is delayed.
Although most people are unlikely to be exposed, experts recommend:
If you feel ill and experience the symptoms of Legionnaire's, watch for signs, especially respiratory distress, fever, or extreme tiredness. Health officials recommend the following:
New York City health officials are testing cooling towers and other potential environmental sources in the affected neighborhoods to identify where the bacteria may have originated. Property owners are immediately required to disinfect contaminated cooling towers if Legionella is detected.
Officials have emphasized that residents can continue using home air conditioners and public cooling centers, as these systems do not typically spread the bacteria in the same way as large industrial cooling towers.
Credit: AI-generated image
The Maharashtra Food and Drug Administration (FDA) recently banned the sale, distribution, and use of several fairness creams after dangerous levels of toxic heavy metals, including lead and mercury, were found in the products.
Among the products, one named Goree Beauty Cream is of Pakistani origin. The product was reportedly being sold unlawfully in the state.
The FDA labelled the products “Not of Standard Quality” (NSQ), warning consumers against using them as prolonged exposure to heavy metals present in the products can lead to serious health complications associated with skin, kidneys as well as the nervous system.
According to the Maharashtra FDA, the following cosmetic products have been declared unsafe:
Officials also noted that the products lacked mandatory information like the manufacturer's complete details, batch number, manufacturing date, and expiry date, raising concerns over their authenticity and safety.
If used repeatedly, these toxic substances may be absorbed through the skin, allowing them to accumulate in the body over time.
Excessive exposure to mercury can cause:
The risk increases with prolonged use, particularly when the products are used on a daily basis over months or years.
Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?
On the other hand, lead exposure can cause:
Even if lead accumulates in the body in small amounts, its repeated use may pose long-term health risks.
Sometimes, mercury is illegally added to skin-lightening products as it suppresses melanin production, temporarily making the skin appear lighter. However, this skin-lightening effect comes at the cost of significant health risks.
Lead may contaminate cosmetic products through poor-quality raw materials or unsafe manufacturing processes. Neither ingredient should be intentionally present in cosmetic creams sold for routine use.
International health agencies have repeatedly warned against skin-lightening creams containing mercury.
In June 2026, the US FDA again cautioned consumers not to use over-the-counter skin-lightening products found to contain mercury or hydroquinone because of the risk of kidney injury, neurological damage, and permanent skin problems.
The Maharashtra FDA's crackdown highlights the hidden dangers of unregulated and illegal fairness creams that contain harmful ingredients.
While these products may promise lighter skin, the presence of toxic heavy metals such as mercury and lead can expose users to potentially irreversible health damage. Consumers are advised to read the labels carefully before purchasing any skincare products that promise complexion-altering effects.
© 2024 Bennett, Coleman & Company Limited